文献速递前列腺癌

雄激素受体变体在前列腺癌中的作用:2017年任务会议报告

Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting.
PubMed 文献 · Eur Urol · 2017-12-16

2017年5月11日波士顿会议汇集国际专家,探讨雄激素受体变体(AR-Vs)作为去势抵抗性前列腺癌(CRPC)生物标志物、进展驱动因素和治疗靶点的作用。会议达成关键共识:进一步研究AR-Vs是CRPC重要研究方向;检测AR变体(如AR-V7)可识别现有AR靶向治疗预后差的患者群体。

要点

  • AR-Vs是CRPC研究重点,需进一步明确其在CRPC进展中的精确作用。
  • 检测AR变体(如AR-V7)可识别对现有AR靶向治疗预后差的患者。
  • 血液检测的发展已支持基于AR变体的治疗选择。

核心结论

  • 会议达成关键共识:进一步研究AR-Vs是CRPC的重要研究方向。
  • 检测AR变体(如AR-V7)可识别对现有AR靶向治疗预后差的患者群体,凸显新型治疗药物的需求。

主要发现

  • 会议聚焦三个主题:AR-Vs作为治疗抵抗生物标志物的潜力、作为功能性CRPC进展驱动因素的作用、作为CRPC治疗靶点的效用。
  • 参会者提出了由数据支持的不同观点和侧重点,并在报告中综合。

临床怎么用

  • 血液检测的发展已支持基于AR变体的治疗选择。
  • 检测AR变体(如AR-V7)可识别对现有AR靶向治疗预后差的患者,凸显新型治疗药物(正在开发中)的需求。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Although a number of studies have demonstrated the importance of constitutively active androgen receptor variants (AR-Vs) in prostate cancer, questions still remain about the precise role of AR-Vs in the progression of castration-resistant prostate cancer (CRPC). OBJECTIVE: Key stakeholders and opinion leaders in prostate cancer convened on May 11, 2017 in Boston to establish the current state of the field of AR-Vs. EVIDENCE ACQUISITION: The meeting "Mission Androgen Receptor Variants" was the second of its kind sponsored by the Prostate Cancer Foundation (PCF). This invitation-only event was attended by international leaders in the field and representatives from sponsoring organizations (PCF and industry sponsors). Eighteen faculty members gave short presentations, which were followed by in-depth discussions. Discussions focused on three thematic topics: (1) potential of AR-Vs as biomarkers of therapeutic resistance; (2) role of AR-Vs as functionally active CRPC progression drivers; and (3) utility of AR-Vs as therapeutic targets in CRPC. EVIDENCE SYNTHESIS: The three meeting organizers synthesized this meeting report, which is intended to summarize major data discussed at the meeting and identify key questions as well as strategies for addressing these questions. There was a critical consensus that further study of the AR-Vs is an important research focus in CRPC. Contrasting views and emphasis, each supported by data, were presented at the meeting, discussed among the participants, and synthesized in this report. CONCLUSIONS: This article highlights the state of knowledge and outlines the most pressing questions that need to be addressed to advance the AR-V field. PATIENT SUMMARY: Although further investigation is needed to delineate the role of androgen receptor (AR) variants in metastatic castration-resistant prostate cancer, advances in measurement science have enabled development of blood-based tests for treatment selection. Detection of AR variants (eg, AR-V7) identified a patient population with poor outcomes to existing AR-targeting therapies, highlighting the need for novel therapeutic agents currently under development.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Luo J, Attard G, Balk SP, et al. Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. Eur Urol. 2017. PMID: 29258679. doi:10.1016/j.eururo.2017.11.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。